Affiliations: [a] Daugavpils University, Daugavpils, Latvia | [b] Riga Stradins University, Riga, Latvia | [c] Latvian Centre of Oncology, Riga, Latvia
Correspondence:
[*]
Corresponding author: Dr. Inta Kalnina, Daugavpils University, Centre of Innovative Microscopy, Parades Str. 1, Daugavpils, LV-5400, Latvia. Tel.: +371 29483597; Fax: +371 67225039; E-mail: mafconf@inbox.lv.
Abstract: The fluorescent probe ABM was used to characterize lymphocyte membranes and blood plasma albumin from cancer patients suffering from colorectal cancer or gastric cancers at Stages II-IV. The aim of these studies was to evaluate the potential utility of measures of ABM fluorescence intensity as a standard tool in the analyses of host immune status and for a clinical interpretation of alterations in albumin per se and lymphocyte functional activity in cancer patients. The fluorescence intensity of ABM in the blood plasma decreased from control values and showed specific differences in each of the differing patients groups; these changes corresponded to cancer stage. The significant decrease in ABM fluorescence in the plasma could be explained, in part, by a diminished binding capacity of the albumin of these patients. The lymphocyte distribution among the subsets of patients also differed. Interestingly, the ABM fluorescence in the cell suspension and blood plasma was also found to correlate with select immunological parameters (CD4+: CD8+ ratios, lymphocyte counts, etc.) in the patients. These results obtained here showed that there was a strong agreement between changes in ABM spectral characteristics and both clinical and pathological estimates of disease (i.e., gastrointestinal cancers) severity. Thus, the use of ABM spectroscopy appears to be another tool that might be of some used by clinicians to monitor the course of certain diseases, such as gastrointestinal cancers.
Keywords: Fluorescent probe, blood plasma albumin, immune status
